Wed.Jun 11, 2025

article thumbnail

FDA Approves Polypill Widaplik for Hypertension

Drugs.com

WEDNESDAY, June 11, 2025 -- The U.S. Food and Drug Administration has approved Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults.The combination pill is the first and only FDA-approved triple combination.

article thumbnail

SpliceBio lands $135M for a new kind of eye gene therapy

BioPharma Drive: Drug Pricing

The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to help overcome the packaging constraints of current genetic medicines.

Packaging 247
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientists discover natural cancer-fighting sugar in sea cucumbers

Science Daily: Pharmacology News

Sea cucumbers, long known for cleaning the ocean floor, may also harbor a powerful cancer-fighting secret. Scientists discovered a unique sugar in these marine creatures that can block Sulf-2, an enzyme that cancer cells use to spread. Unlike traditional medications, this compound doesn t cause dangerous blood clotting issues and offers a cleaner, potentially more sustainable way to develop carbohydrate-based drugs if scientists can find a way to synthesize it in the lab.

Drugs 222
article thumbnail

Real-World Results For GLP-1 Drugs Underwhelm, Study Says

Drugs.com

WEDNESDAY, June 11, 2025 — Real-world results for blockbuster weight-loss meds like Ozempic, Wegovy and Zepbound aren’t as impressive as those promised by the drugs’ clinical trials, a new study says. People taking such GLP-1.

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal

BioPharma Drive: Drug Pricing

The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate cancer that works differently than Novartis’ Pluvicto.

173
173
article thumbnail

FDA Plans to Use AI to Speed Up Drug and Food Safety Reviews

Drugs.com

WEDNESDAY, June 11, 2025 — The U.S. Food and Drug Administration (FDA) says it plans to use artificial intelligence (AI) to help speed the approval of new drugs and medical devices. That's one of several priorities federal officials detailed.

FDA 166

More Trending

article thumbnail

Scientists found the brain glitch that makes you think you’re still hungry

Science Daily: Pharmacology News

A team of scientists has identified specialized neurons in the brain that store "meal memories" detailed recollections of when and what we eat. These engrams, found in the ventral hippocampus, help regulate eating behavior by communicating with hunger-related areas of the brain. When these memory traces are impaired due to distraction, brain injury, or memory disorders individuals are more likely to overeat because they can't recall recent meals.

article thumbnail

Top Scientific Data Platforms for AI-Driven Drug Discovery: What to Look For

Collaborative Drug

Compare top scientific data platforms for AI-driven drug discovery. Evaluate CDD Vault, Dotmatics, Benchling & more for chemistry and biologics workflows.

Drugs 130
article thumbnail

At-Home HPV Testing Boosts Cervical Cancer Screening Rates

Drugs.com

WEDNESDAY, June 11, 2025 — Women will flock to an HPV test they can perform at home in private, a new study indicates. Cervical cancer screening more than doubled when women were offered a mail-in self-collection test for human papillomavirus.

180
180
article thumbnail

This mind-bending physics breakthrough could redefine timekeeping

Science Daily: Pharmacology News

By using a clever quantum approach that involves two "hands" on a clock one moving quickly and invisibly in the quantum world, the other more traditionally scientists have found a way to boost timekeeping precision dramatically. Even better, this trick doesn't require a matching increase in energy use. The discovery not only challenges long-held beliefs about how clocks and physics work, but could also lead to powerful new tools in science, technology, and beyond.

Science 205
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Biking Might Promote Healthy Brain Aging

Drugs.com

WEDNESDAY, June 11, 2025 — Want to reduce your risk of dementia and Alzheimer’s disease? Get on your bike and ride, a new study recommends. Biking regularly for transportation appears to lower risk of dementia by 19% and.

Disease 240
article thumbnail

Targeting Cancer Cell Proliferation Using Piperazine‐Linked Quinolinequinones: Mechanism and Metabolic Profile

Chemical Biology and Drug Design

We examined the quinolinequinones' ( QQ1- 7 ) effects on cancer cell lines. The most potent compound was QQ1 against ACHN cells with an IC50 value of 1.5 ± 0.16 μM. For better understanding, the effects of QQ1 on apoptosis, cell cycle, and oxidative stress were investigated. QQ1 inhibited ACHN cell proliferation via cell cycle arrest. The host-guest interactions of quinolinequinones were also studied in detail using thorough in silico docking simulations with pharmacokinetic studies.

article thumbnail

These Smiling Salamanders Are Helping Scientists Learn to Regrow Limbs

Drugs.com

WEDNESDAY, June 11, 2025 — With their goofy grins and feathery gills, axolotls have become stars of the pet world and video games like Minecraft. But these small, smiling salamanders are also helping scientists explore a medical mystery: Can.

183
183
article thumbnail

Broad Institute and Bayer extend their cardiovascular alliance

Broad Institute

Broad Institute and Bayer extend their cardiovascular alliance By Leah Eisenstadt June 11, 2025 Breadcrumb Home Broad Institute and Bayer extend their cardiovascular alliance Partnership will continue with renewed focus on developing new cardiovascular therapies. By Broad Communications June 11, 2025 Related news Broad Institute and Bayer expand cardiovascular alliance Broad Institute of MIT and Harvard and Bayer Healthcare expand their partnership to develop therapies for cardiovascular disease

Disease 93
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Sun’s secret storms exposed: NASA's codex unveils a turbulent corona

Science Daily: Pharmacology News

NASA s CODEX experiment aboard the International Space Station is revealing the Sun like never before. Using advanced filters and a specialized coronagraph, CODEX has captured images showing that the solar wind streams of charged particles from the Sun is not a smooth, uniform flow but rather a turbulent, gusty outpouring of hot plasma. These groundbreaking observations will allow scientists to measure the speed and temperature of the solar wind with unprecedented detail, providing critical insi

article thumbnail

Key Strategies for Successfully Challenging a Drug Patent

Drug Patent Watch

"Patent Puzzle: How to Outmaneuver Big Pharma's Monopolies As the cost of prescription medications continues to skyrocket, patients and healthcare providers are fighting back against Big Pharma's stranglehold on the market. But with billions of dollars in research and development at stake, the pharmaceutical industry will stop at nothing to protect its intellectual property.

Drugs 90
article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Drug development is plagued by complex challenges, but multimodal AI is unlocking new opportunities. By integrating diverse data sources – from genomics to clinical insights – this approach is accelerating drug discovery, improving patient stratification and boosting success rates. Read on to explore how multimodal AI is reshaping the future of medicine.

Drugs 64
article thumbnail

Gepirone

New Drug Approvals

Gepirone CAS 83928-76-1 BMY 13805, MJ 13805, ORG 13011, Gepirona, JW5Y7B8Z18 FDA 9/22/2023, Gepirone is indicated for the treatment of major depressive disorder (MDD) in adults Exxua Weight Average: 359.474 Monoisotopic: 359.232125194 Chemical Formula C 19 H 29 N 5 O 2 4,4-dimethyl-1-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}piperidine-2,6-dione Ingredient UNII CAS InChI Key Gepirone Hydrochloride 80C9L8EP6V 83928-66-9 DGOCVISYYYQFEP-UHFFFAOYSA-N Gepirone , sold under the brand name Exxua , is

FDA 62
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Accelerated Molecular Modeling with NVIDIA cuEquivariance and NVIDIA NIM microservices

Nvidia Developer: Drug Discovery

The emergence of models like AlphaFold2 has skyrocketed the demand for faster inference and training of molecular AI models. The need for speed comes with. The emergence of models like AlphaFold2 has skyrocketed the demand for faster inference and training of molecular AI models. The need for speed comes with unique computational challenges, including algorithmic complexity, memory efficiency, and strict accuracy requirements.

Drugs 65
article thumbnail

'Latchkey Incontinence' Treatments Might Include Mindfulness Meditation

Drugs.com

WEDNESDAY, June 11, 2025 — Ever get the sudden urge to pee once you’ve seen your front door, slipped your key into the lock or pushed the remote to open your garage door? That’s a phenomenon known as “latchkey.

Treatment 147
article thumbnail

Patient Tumor Samples and Mass Spectrometry: Unveiling Molecular Signatures in Cancer Research

Crown Bioscience

The integration of patient tumor samples and mass spectrometry is reshaping the landscape of cancer research and precision medicine. As researchers and clinicians seek to understand the complexities of cancer at a molecular level, high-resolution analytical techniques have become essential. Mass spectrometry (MS), when applied to patient-derived tumor tissues, allows for comprehensive profiling of proteins, lipids, metabolites, and post-translational modifications—offering insights into tumor bi

article thumbnail

Inflammatory Bowel Disease Info Lacking On TikTok

Drugs.com

WEDNESDAY, June 11, 2025 — Many folks with inflammatory bowel disease (IBD) are turning to TikTok for advice, but they aren’t likely to receive useful and accurate information, a new study says. Analysis of 86 top IBD videos with a.

Disease 130
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Bayer Pharma Selects Rege Nephro and NXI Therapeutics Through Halo to Join New Co.Lab Connect Program

Translation

Bayer Pharma has named Rege Nephro , a clinical-stage biotech startup from Japan and NXI Therapeutics , an immunotherapy startup based in Switzerland, as the first companies selected for its new Co.Lab Connect program: an initiative designed to help life sciences startups expand globally by bridging them into the Boston-Cambridge innovation ecosystem.

Science 52
article thumbnail

Bristol Myers Squibb Unveils Positive Phase 3 Data for Sotyktu in Psoriatic Arthritis

The Pharma Data

Bristol Myers Squibb Unveils Compelling Late-Breaking Phase 3 Data Highlighting the Efficacy of Sotyktu (Deucravacitinib) in Treating Psoriatic Arthritis Bristol Myers Squibb has announced new late-breaking clinical data from the pivotal Phase 3 POETYK PsA-1 trial, reinforcing the potential of its oral, selective TYK2 inhibitor, Sotyktu® (deucravacitinib) , as an effective treatment for adults with active psoriatic arthritis (PsA).

Trials 40
article thumbnail

From Fragments To Clarity: Empowering Research with Complete Patient Data

Fierce BioTech

From Fragments To Clarity: Empowering Research with Complete Patient Data Learn how natural language processing (NLP) unlocks critical insights from unstructured EHR data—like physician notes and patient narratives—to give researchers a complete view of the patient journey. See how combining structured and unstructured data advances drug development.

article thumbnail

argenx Unveils Positive Efgartigimod Phase 2 Data in Myositis and Sjogren’s at EULAR 2025

The Pharma Data

argenx Unveils Positive Phase 2 Results for Efgartigimod in Myositis and Sjogren’s Disease at EULAR 2025 argenx SE a global immunology company dedicated to advancing treatments for severe autoimmune diseases, presented encouraging new clinical data at the 2025 European Congress of Rheumatology (EULAR), held June 11–14 in Barcelona, Spain. The data come from Phase 2 trials evaluating its investigational therapy VYVGART® (efgartigimod) for two hard-to-treat autoimmune conditions: idiopathic inflam

Disease 40
article thumbnail

Forging the Future: Why Strategic Outsourcing in Biologics is No Longer Optional, It's Essential for Success

Fierce BioTech

The biologics revolution is in full swing, and as innovation accelerates, so does the complexity of bringing these life-changing therapies to market. | The biologics revolution is in full swing, and as innovation accelerates, so does the complexity of bringing these life-changing therapies to market. With the BIO International Convention on the horizon, the corridors will be buzzing with talk of groundbreaking science.

article thumbnail

FDA Approves Tablet Form of BeOne’s BRUKINSA® for All Indications

The Pharma Data

FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications, Offering Greater Convenience for Patients with B-cell Cancers BeOne Medicines Ltd. a global oncology-focused biopharmaceutical company, has received a significant regulatory milestone from the U.S. Food and Drug Administration (FDA). The agency has officially approved a new tablet formulation of BRUKINSA® (zanubrutinib) for all five of its previously approved indications.

article thumbnail

Utilizing AI-Powered Structured Content Authoring for Global ePI Compliance

Fierce BioTech

Utilizing AI-Powered Structured Content Authoring for Global ePI Compliance Learn how to streamline ePI compliance with AI-powered tools and meet global mandates—essential insights for regulatory and content leaders. Download this whitepaper today. sdees Wed, 06/11/2025 - 13:38 Learn how to streamline ePI compliance with AI-powered tools and meet global mandates—essential insights for regulatory and content leaders.

article thumbnail

First Patient Dosed in Phase 3 REVEAL Trial of ION582 for Angelman Syndrome

The Pharma Data

Ionis Begins Pivotal Phase 3 REVEAL Study of ION582 in Angelman Syndrome, Dosing First Patient in Global Trial Ionis Pharmaceuticals , Inc. (Nasdaq: IONS) has announced the dosing of the first patient in the Phase 3 REVEAL clinical trial, marking a significant milestone in the development of ION582, an investigational therapy for Angelman syndrome (AS).

Trials 40
article thumbnail

An “Inconceivable” Conversation With Dr. Pete Cornwell on Simple vs. Agentic AI

Perficient: Drug Development

Dr. Pete Cornwell, Director of Contact Center, offers a fresh perspective on customer care and is sharing his wealth of knowledge at Customer Contact Week in Las Vegas. With over 35 years of experience spanning information systems, design, architecture, and consulting for industry leaders like Terazo and Blue Cross Blue Shield North Carolina, his expertise runs deep.

article thumbnail

Dapirolizumab Pegol Phase 3 Data Shows SLE Fatigue and Disease Activity Improvement at EULAR

The Pharma Data

Dapirolizumab Pegol Demonstrates Promise in Phase 3 SLE Trial, Showing Improvements in Fatigue and Disease Activity at EULAR 2025 UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) presented comprehensive new findings from their Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP) at the 2025 Annual Congress of the European Alliance of Associations for Rheumatology (EULAR) in Barcelona, Spain.

Disease 40